Targeted intrapulmonary delivery of drugs may reduce systemic toxicity and
Invasive pulmonary aspergillosis (IPA) results in significant morbidity and mortality in severe immunocompromised patients (6). Targeted intrapulmonary delivery of antifungals has potential to reduce systemic toxicity, improve treatment efficacy as well as prophylaxis (1, 8) , and may be used as an optional route in combination use with other systemic antifungals. In the current study, we evaluated the efficacy of aerosolized liposomal amphotericin B (L-AMB) either in single and combination with intraperitoneally administered micafungin (MCFG) in a murine model of IPA.
histopathological examination. Mice were immunosuppressed by subcutaneous injection of cortisone acetate (Sigma, Tokyo, Japan) at 250 mg/kg and intraperitoneal cyclophosphamide (Sigma) at 200 mg/kg on days -2, 0 for survival study. Whereas, only cortisone acetate 200 mg/kg was used on days -1, 0 and 1 for fungal burden analysis and histopathological examination. Mice were assigned into the following groups, 1) control, 2) intraperitoneal MCFG, 3) aerosolized L-AMB and 4) combination of intraperitoneal MCFG and aerosolized L-AMB treatment. Each group is consisted of 11 and 10 mice for survival and fungal burden analysis, respectively. MCFG was administered intraperitoneally once daily at 1 mg/kg/day. L-AMB was administered once daily at a dose of 8 ml of 1.2 mg/ml per inhalation. Antifungals were initiated 16 hours after inoculation and continued for 5 and 3 days for survival and fungal burden analysis, respectively. The L-AMB solution was aerosolized using a nebulizer (Muromachi kikai Co., Ltd., Tokyo, Japan) and mice were exposed to aerosol treatment for 60 min as previously described (9). Control mice were treated with sterile saline. Survival was observed until 11 days following the challenge. For fungal burden and hisotpathologcal examinations, mice were sacrificed 4 hours after treatment of day 3. CFU per lung tissue were calculated and removed lungs were fixed and stained with Grocott's methenamine silver nitrate and hematoxylin-eosin as previously described (11).
Survival and fungal burden data are presented in combined of two sets of experiments.
The blood concentration and the pharmacokinetics of aerosolized L-AMB were evaluated. Uninfected mice were also exposed to several concentrations of aerosolized L-AMB for 5 days and blood samples and lungs were collected. AMB concentration was quantified as previously described (10). Survival curves were generated using the Kaplan and Meier method and statistical differences were evaluated by the log rank test.
To assess fungal burden in lung tissue, geometric means of CFU per organ were compared by Student's t test. Statistical significance was defined as P < 0.05.
The MIC of AMB against A. fumigatus MF-13 was 1.0 μg/ml and the MEC of MCFG was 0.0315 μg/ml. FIC index of AMB and MCFG was 1.5 and drug interaction was classified as indifferent (5).
Survival periods of monotherapy groups, in which mice were treated with either intraperitoneal MCFG or aerosolized L-AMB inhalation were significantly longer than that of the control group (MCFG alone vs. control, P = 0.006; L-AMB vs. control, P < 0.001) (Figure 1 ). The combination treatment group showed significantly longer survival than the intraperitoneal MCFG (P < 0.001), aerosolized L-AMB (P = 0.037) and control (P < 0.001) groups. Lung CFU of combination-treated group was significantly reduced compared to each of the intraperitoneal MCFG (P < 0.001), Recorded levels in the serum were 0.02, 0.06 and 0.06 μg/ml when inhaled L-AMB suspensions were administered at 1.2, 2.6 and 4.0 mg/ml, respectively.
The current study demonstrated the efficacy of monotherapy of aerosolized L-AMB in murine IPA model. AMB concentration in lung tissue in our study was relatively higher with extremely lower in serum compared to data from another report of murine intravenous L-AMB administered model, although experimental conditions were not same (10). These results suggested that systemic toxicity generally caused by AMB treatment may be reduced by L-AMB inhalation therapy.
The effect of combined intraperitoneal MCFG and aerosolized L-AMB treatment demonstrated an enhanced survival rate, even though this drug interaction was classified as indifferent in vitro. Since 78% of all control mice died in first three days in survival analysis, we changed the experimental conditions for analysis of fungal burden and histopathological examination. In this model, no mice died before euthanasia, a prerequisite for organ CFU assay. Both fungal burden data and histopathological findings supported the survival data in our study.
In contrast to our study, Graybill et al. previously reported that combination therapy demonstrated a lack of synergistic effects following intravenous L-AMB and intraperitoneal MCFG treatment in murine IPA (4). These discrepancies are likely due to differences between our model and Graybill's model including 1) the route of infection, 2) status of immunosuppression and 3) the administration route of antifungal drugs.
These differences also suggest that targeted intrapulmonary delivery of drugs by inhalation raises the drug concentration at the active site of infection in the lungs, thus contributing to the efficacy of combination therapy. Further comparative efficacy studies in a clinical setting are warranted. 
